The recent consolidations among national hospital groups has left many suppliers feeling a significant loss of leverage in contract negotiations. But what hospitals don't realize is that consolidation on the supplier side, due to market attrition and increased merger and acquisitions, has created suppliers nearly invulnerable to competitive pressure. As the number of players on both sides of the table shrinks, has consolidation in hospital supply gone too far?
by David Cassak
In 1990, AmeriNet Inc. , the St. Louis-based hospital purchasing group, faced a touchy situation.Executives at the largest of...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
